NasdaqGS:APLSBiotechs
Apellis Pharmaceuticals (APLS) Profitability Shift Tests Bullish Narratives After Q4 Loss
Apellis Pharmaceuticals (APLS) capped FY 2025 with Q4 revenue of US$199.9 million and basic EPS of US$0.47 loss, alongside a net loss of US$59.0 million. On a trailing twelve month basis, the company booked revenue of US$1.0 billion and basic EPS of US$0.18 profit. Over the past year, revenue has moved from US$781.4 million to US$1.0 billion on a trailing basis, with EPS shifting from a loss of US$1.60 to a profit of US$0.18. This sets up a story where investors may weigh sustained revenue...